COURAGE trial data lead debate at a lively ACC 2007 meeting
This article was originally published in Clinica
Executive Summary
Featuring as many as 48 late-breaking trial results and a score of emerging technologies, it comes as no surprise that this year's annual meeting of the American College of Cardiology (ACC) was able to secure key coverage in the mainstream press. The four-day meeting, the largest to convene in New Orleans, Louisiana, since Hurricane Katrina in mid-2005, generated a stream of lively debate that has kept industry on its toes since the conference opened on March 24.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.